FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308026457> ?p ?o ?g. }

• W4308026457 abstract "The programmed death-ligand 1 (PD-L1) 22C3 assay is one of the approved companion diagnostic assays for receiving anti-programmed cell death ligand 1 (PD-L1) therapy. Our study evaluated the performance of E1L3N and 22C3 antibodies in estimating PD-L1 expression in non-small cell lung cancer (NSCLC).Our retrospective study included 46 patients diagnosed with unresectable EGFR/ALK/ROS1-negative NSCLC who received first-line pembrolizumab therapy between 2018 and 2021. PD-L1 immunohistochemistry of baseline tissue biopsy samples was performed using PDL1-E1L3N and PDL1-22C3 antibodies. The concordance between the PD-L1 assays and the treatment outcomes was assessed.Using a tumor proportion score (TPS) cutoff of ≥1%, 67.4% of patients are evaluated to be positive using PDL1-E1L3N and 73.9% using PDL1-22C3. Using a TPS of ≥50% as the cutoff, 26.1% of patients are positive using PDL1-E1L3N and 30.4% using PDL1-22C3. The PDL1-22C3 and PDL1-E1L3N assays are highly concordant and reveal a correlation coefficient of 0.925 (p < 0.0001). Patients with PDL1-E1L3N TPS > 50% have a significantly higher objective response rate than patients with PDL1-E1L3N TPS < 1% (p = 0.047), with a similar trend observed for PDL1-22C3 (p = 0.051). Consistent with PDL1-22C3, patients with higher PDL1-E1L3N expression (≥50%, 1-49%) have longer progression-free survival than those with PDL1-E1L3N TPS < 1%.Our study provides clinical evidence on the concordance of PD-L1 TPS scores between clones E1L3N and 22C3. Moreover, the treatment responses to pembrolizumab are also comparable between the PDL1-E1L3N and PDL1-22C3. These findings indicate that E1L3N is a reliable and cost-effective assay and may serve as an alternative to 22C3.To determine which patients might be suitable to receive immunotherapy, a type of cancer treatment that triggers the immune system to target the patient’s tumor, a PD-L1 test is sometimes used. This test looks at the levels of PD-L1, which indicate whether immunotherapy might work in the patient. One of the tests commonly used can be expensive and a reliable and cost-effective alternative is needed. Here, we compare the results of PD-L1 testing with that test with an alternative that is more cost-effective. We show that the two tests are highly concordant, and also demonstrate that the results using the alternative test are able to predict response to immunotherapy in patients with advanced non-small cell lung cancer. Our findings provide evidence that the alternative, more cost-effective test might be useful and reliable in the clinic." @default.
• W4308026457 created "2022-11-07" @default.
• W4308026457 creator A5001219472 @default.
• W4308026457 creator A5032559235 @default.
• W4308026457 creator A5032770951 @default.
• W4308026457 creator A5033825363 @default.
• W4308026457 creator A5036139505 @default.
• W4308026457 creator A5037953219 @default.
• W4308026457 creator A5057020624 @default.
• W4308026457 creator A5057287134 @default.
• W4308026457 creator A5057960953 @default.
• W4308026457 creator A5058391979 @default.
• W4308026457 creator A5076756498 @default.
• W4308026457 creator A5088883583 @default.
• W4308026457 date "2022-11-01" @default.
• W4308026457 modified "2023-10-09" @default.
• W4308026457 title "Validation of E1L3N antibody for PD-L1 detection and prediction of pembrolizumab response in non-small-cell lung cancer" @default.
• W4308026457 cites W1982488143 @default.
• W4308026457 cites W1997878709 @default.
• W4308026457 cites W2057893793 @default.
• W4308026457 cites W2198093519 @default.
• W4308026457 cites W2292383635 @default.
• W4308026457 cites W2398309632 @default.
• W4308026457 cites W2557730509 @default.
• W4308026457 cites W2560367415 @default.
• W4308026457 cites W2569740680 @default.
• W4308026457 cites W2572174216 @default.
• W4308026457 cites W2604812712 @default.
• W4308026457 cites W2743614427 @default.
• W4308026457 cites W2748246139 @default.
• W4308026457 cites W2765696340 @default.
• W4308026457 cites W2769300445 @default.
• W4308026457 cites W2770587120 @default.
• W4308026457 cites W2808160603 @default.
• W4308026457 cites W2883081936 @default.
• W4308026457 cites W2883890283 @default.
• W4308026457 cites W2891760302 @default.
• W4308026457 cites W2892640821 @default.
• W4308026457 cites W2900174742 @default.
• W4308026457 cites W2910245285 @default.
• W4308026457 cites W2925446385 @default.
• W4308026457 cites W2946436481 @default.
• W4308026457 cites W2948046941 @default.
• W4308026457 cites W2968867518 @default.
• W4308026457 cites W2969539132 @default.
• W4308026457 cites W2995123342 @default.
• W4308026457 cites W2998841267 @default.
• W4308026457 cites W3007188668 @default.
• W4308026457 cites W3009099064 @default.
• W4308026457 cites W3036371943 @default.
• W4308026457 cites W3047859155 @default.
• W4308026457 cites W3128294524 @default.
• W4308026457 cites W3152729586 @default.
• W4308026457 cites W3158697155 @default.
• W4308026457 cites W3165007730 @default.
• W4308026457 cites W3167114692 @default.
• W4308026457 doi "https://doi.org/10.1038/s43856-022-00206-4" @default.
• W4308026457 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36352254" @default.
• W4308026457 hasPublicationYear "2022" @default.
• W4308026457 type Work @default.
• W4308026457 citedByCount "2" @default.
• W4308026457 countsByYear W43080264572023 @default.
• W4308026457 crossrefType "journal-article" @default.
• W4308026457 hasAuthorship W4308026457A5001219472 @default.
• W4308026457 hasAuthorship W4308026457A5032559235 @default.
• W4308026457 hasAuthorship W4308026457A5032770951 @default.
• W4308026457 hasAuthorship W4308026457A5033825363 @default.
• W4308026457 hasAuthorship W4308026457A5036139505 @default.
• W4308026457 hasAuthorship W4308026457A5037953219 @default.
• W4308026457 hasAuthorship W4308026457A5057020624 @default.
• W4308026457 hasAuthorship W4308026457A5057287134 @default.
• W4308026457 hasAuthorship W4308026457A5057960953 @default.
• W4308026457 hasAuthorship W4308026457A5058391979 @default.
• W4308026457 hasAuthorship W4308026457A5076756498 @default.
• W4308026457 hasAuthorship W4308026457A5088883583 @default.
• W4308026457 hasBestOaLocation W43080264571 @default.
• W4308026457 hasConcept C121608353 @default.
• W4308026457 hasConcept C126322002 @default.
• W4308026457 hasConcept C143998085 @default.
• W4308026457 hasConcept C159654299 @default.
• W4308026457 hasConcept C160798450 @default.
• W4308026457 hasConcept C203014093 @default.
• W4308026457 hasConcept C204232928 @default.
• W4308026457 hasConcept C2776256026 @default.
• W4308026457 hasConcept C2777701055 @default.
• W4308026457 hasConcept C2780057760 @default.
• W4308026457 hasConcept C2781053074 @default.
• W4308026457 hasConcept C71924100 @default.
• W4308026457 hasConceptScore W4308026457C121608353 @default.
• W4308026457 hasConceptScore W4308026457C126322002 @default.
• W4308026457 hasConceptScore W4308026457C143998085 @default.
• W4308026457 hasConceptScore W4308026457C159654299 @default.
• W4308026457 hasConceptScore W4308026457C160798450 @default.
• W4308026457 hasConceptScore W4308026457C203014093 @default.
• W4308026457 hasConceptScore W4308026457C204232928 @default.
• W4308026457 hasConceptScore W4308026457C2776256026 @default.
• W4308026457 hasConceptScore W4308026457C2777701055 @default.
• W4308026457 hasConceptScore W4308026457C2780057760 @default.
• W4308026457 hasConceptScore W4308026457C2781053074 @default.
• W4308026457 hasConceptScore W4308026457C71924100 @default.

• next